Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls

Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls

Abstract Patients with multiple myeloma are at high risk of severe forms of COVID-19. Despite data showing diminished response to vaccine, the era of highly efficient mRNA vaccine might be a gamechanger. We sought to examine response to mRNA vaccine between healthy controls (n = 28) and multiple mye...

Full description

Bibliographic Details
Main Authors: Samuel Bitoun, Julien Henry, Christelle Vauloup-Fellous, Nicolas Dib, Rakiba Belkhir, Lina Mouna, Candie Joly, Delphine Desjardins, Marie Bitu, Roger Le Grand, Raphaèle Seror, Anne-Marie Roque Afonso, Xavier Mariette
Format: Article
Language:English
Published: BMC 2021-10-01
Series:Journal of Hematology & Oncology
Subjects:
Multiple myeloma
Daratumumab
SARS-COV-2
Vaccine
COVID-19
Neutralization
Online Access:https://doi.org/10.1186/s13045-021-01183-2

Internet

https://doi.org/10.1186/s13045-021-01183-2

Similar Items